Is Haemonetics (HAE) Undervalued? A Fresh Look at the Company’s Current Valuation

Haemonetics (HAE) has seen its share price move within a tight range lately, which has sparked some curiosity among investors watching for the company’s next catalyst. As recent returns remain under pressure, valuation comes into focus.

See our latest analysis for Haemonetics.

While Haemonetics’ share price has been treading water, there have been no dramatic swings or news headlines to spark new momentum. Investors are watching closely as this muted share price movement contrasts with a long-term total shareholder return that has edged slightly lower. This highlights how shifts in growth expectations and risk perceptions are weighing on broader performance and valuation outlooks.

If you’re curious about which healthcare stocks might be showing more momentum or untapped potential, check out the latest picks on our See the full list for free..

With the stock lingering below analyst targets despite underlying earnings growth, is Haemonetics now undervalued and primed for recovery? Or is the market simply cautious and already anticipating its future prospects?

Most Popular Narrative: 37.8% Undervalued

According to the most widely followed narrative, Haemonetics' estimated fair value is significantly above the last close, suggesting the stock could be set for a rebound given current pricing. While the market remains cautious, analysts’ higher expectations set a contrasting tone for the company's prospects.

Accelerated innovation, portfolio transformation, and software adoption are driving share gains, margin expansion, and sustained revenue growth across both plasma and hospital markets. Demographic shifts and increased demand for blood management position core products for long-term growth. Targeted interventions aim to revitalize underperforming segments.

Read the complete narrative.

Curious what solid assumptions are driving this steep gap between price and narrative fair value? Find out what earnings, margin, and growth projections power this fresh outlook. See the numbers that could change the trajectory if they play out as expected.

Result: Fair Value of $78.64 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, intensifying competition and heavy reliance on core U.S. products could threaten Haemonetics’ earnings stability and undermine the anticipated recovery narrative.

Find out about the key risks to this Haemonetics narrative.

Build Your Own Haemonetics Narrative

If you have your own perspective or want to dig deeper into the financials and forecasts, try building your own Haemonetics narrative in just a few minutes. Do it your way

A great starting point for your Haemonetics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t miss out on high-potential opportunities. Expand your investment radar with smart stock-picking tools trusted by investors worldwide.

• Spot rare value plays by screening these 914 undervalued stocks based on cash flows that analysts think the market has overlooked, and get a head start on tomorrow’s leaders.
• Capture the latest innovation wave by targeting these 23 AI penny stocks shaping automation, intelligent software, and tomorrow’s data-driven trends.
• Strengthen your portfolio’s income stream with these 19 dividend stocks with yields > 3% that offer reliable payouts above 3% and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com